Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study
Ramin Tehranchi, Jonas Pettersson, Anita E Melgaard, Friedeborg Seitz, Anders Valeur, Stine Just Maarbjerg, Ramin Tehranchi, Jonas Pettersson, Anita E Melgaard, Friedeborg Seitz, Anders Valeur, Stine Just Maarbjerg
Abstract
Background: Dasiglucagon is a novel glucagon analog that is stable in aqueous formulation and approved for use in severe hypoglycemia. Concentration QTc analyses are critical for assessing risk of drug-induced QTc prolongation and potential for fatal cardiac arrhythmias such as torsades de pointes.
Objective: The aim of this study was to determine whether dasiglucagon treatment resulted in any clinically relevant effect on cardiac repolarization in healthy volunteers.
Methods: This double-blind, placebo-controlled, dose-escalation Phase I trial was conducted at a single center in Germany between November 2018 and June 2019. Sixty healthy volunteers aged 18 to 45 years were randomized within dose cohorts to receive intravenous dasiglucagon, intravenous placebo, or subcutaneous dasiglucagon. In the intravenous administration cohorts, doses ranged from 0.03 mg to 1.5 mg. The subcutaneous administration cohort received the approved 0.6 mg dose. In the intravenous administration cohorts, serial electrocardiograms were extracted from continuous Holter monitors at prespecified time points beginning the day before dosing and through 24 hours postdose. Heart rate, PR interval, and QRS duration were evaluated. Concentration-QT analyses corrected by Fridericia's formula (QTcF) were performed using both a linear mixed-effects and a maximum estimated effect (Emax) model.
Results: At the doses studied, dasiglucagon did not have any clinically relevant effect on heart rate, PR interval, or QRS duration. A minor prolongation of the QTcF interval was observed without any clear dose or concentration dependency. Both the linear and Emax models predicted mean and 90% CIs of placebo-corrected change in QTcF remained below 10 ms (the threshold of regulatory concern), although the linear model did not fit the data well at low dasiglucagon plasma concentrations. In the Emax model, the Emax of dasiglucagon was 3.6 ms (90% CI, 1.23-5.95 ms), and the amount to produce half the effect of Emax) was 426.0 pmol/L (90% CI, -48.8 to 900.71 pmol/L). The treatment effect-specific intercept was -0.44 ms (90% CI, -2.37 to 1.49 ms). The most frequently observed treatment-emergent adverse events reported in the trial were gastrointestinal disorders such as nausea and vomiting.
Conclusions: Dasiglucagon does not cause clinically relevant QTc prolongation in concentrations up to ≈30,000 pmol/L, a level 5-fold higher than the highest observed plasma concentrations in clinical trials investigating use of the approved 0.6 mg SC dose. ClinicalTrials.gov Identifier: NCT03735225; EudraCT identifier: 2018-002025-32. (Curr Ther Res Clin Exp. 2022; 83:XXX-XXX).
Keywords: Cardiac repolarization; Concentration-QTc analysis; Dasiglucagon; Pharmacokinetics.
Conflict of interest statement
This study was funded by Zealand Pharma (Søborg, Denmark). R. Tehranchi, S. J. Maarbjerg, J. Pettersson, A. E. Melgaard, and A. Valeur are employees of Zealand Pharma. As authors, employees of Zealand Pharma were involved in the study design; collection, analysis, and interpretation of data; the writing of the manuscript; and the decision to submit the manuscript for publication. The authors have indicated that they have no other conflicts of interest regarding the content of this article.
© 2022 Published by Elsevier Inc.
Figures
References
- Chabenne JR, Mroz PA, Mayer JP, DiMarchi RD. Structural Refinement of Glucagon for Therapeutic Use. J Med Chem. 2020;63:3447–3460.
- Pujadas G, Drucker DJ. Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance. Endocr Rev. 2016;37:554–583.
- Petersen KM, Bogevig S, Holst JJ, Knop FK, Christensen MB. Hemodynamic Effects of Glucagon: A Literature Review. J Clin Endocrinol Metab. 2018;103:1804–1812.
- Petersen KM, Bogevig S, Riis T, et al. High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial. J Am Heart Assoc. 2020;9
- Zhang K, Lehner LJ, Praeger D, et al. Glucagonoma-induced acute heart failure. Endocrinol Diabetes Metab Case Rep. 2014;2014
- Chang-Chretien K, Chew JT, Judge DP. Reversible dilated cardiomyopathy associated with glucagonoma. Heart. 2004;90:e44.
- Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension. 1997;30:1267–1273.
- Hovelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 2018;41:531–537.
- Pieber TR, Aronson R, Hovelmann U, et al. Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021;44:1361–1367.
- Garnett C, Bonate PL, Dang Q, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45:383–397.
- Taubel J, Lorch U, Ferber G, et al. Insulin at normal physiological levels does not prolong QT(c) interval in thorough QT studies performed in healthy volunteers. Br J Clin Pharmacol. 2013;75:392–403.
- Taubel J, Ferber G, Van Langenhoven L, et al. The Cardiovascular Effects of a Meal: J-Tpeak and Tpeak-Tend Assessment and Further Insights Into the Physiological Effects. J Clin Pharmacol. 2019;59:799–810.
- Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia. 2000;43:571–575.
- Cirincione B, Sager PT, Mager DE. Influence of Meals and Glycemic Changes on QT Interval Dynamics. J Clin Pharmacol. 2017;57:966–976.
- Gastaldelli A, Emdin M, Conforti F, Camastra S, Ferrannini E. Insulin prolongs the QTc interval in humans. Am J Physiol Regul Integr Comp Physiol. 2000;279:R2022–R2025.
- Global Instrumentations. M12 Holter & ECG recorder. 2021. Accessed August 16, 2021. .
- Darpo B, Fossa AA, Couderc JP, et al. Improving the precision of QT measurements. Cardiol J. 2011;18:401–410.
- Pieber TR, Ajala O, Steen O, Dahl D, Hansen LE, Tehranchi R. Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes. Diabetes Technol Ther. 2021;23:773–776.
- Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol. 2003;8:343–351.
- Isner JM, Sours HE, Paris AL, Ferrans VJ, Roberts WC. Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of the prolonged QT interval. Circulation. 1979;60:1401–1412.
- Nagy D, DeMeersman R, Gallagher D, et al. QTc interval (cardiac repolarization): lengthening after meals. Obes Res. 1997;5:531–537.
- Zealand Pharma A/S. Zegalogue (dasiglucagon) for injection. 2021. Accessed March 29, 2021. .
Source: PubMed